Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon™ PTH as a Replacement Therapy for Hypoparathyroidism
April 19, 2020 16:00 ET | Ascendis Pharma
– PaTH Forward Trial met key objectives and showed that TransCon PTH eliminated standard of care in 82 percent of subjects within four weeks –– Conference call today at 6 p.m. Eastern Time to...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Reports Second Quarter 2019 Financial Results
August 28, 2019 16:01 ET | Ascendis Pharma A/S
– TransCon hGH moves towards Biologics License Application submission following completion of heiGHt and fliGHt Trials – – Global reach of endocrinology rare disease programs expands – – Conference...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Announces Participation in August Investor Conferences
July 29, 2019 08:00 ET | Ascendis Pharma A/S
COPENHAGEN, Denmark, July 29, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Reports First Quarter 2019 Financial Results
May 30, 2019 16:02 ET | Ascendis Pharma A/S
– Continued execution of global endocrinology rare disease programs, following validation of TransCon™ platform in phase 3 heiGHt Trial – – R&D Day on June 26 to feature endocrinology and...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Announces Poster Presentation on TransCon Technology at the Controlled Release Society Annual Meeting
July 23, 2018 16:44 ET | Ascendis Pharma A/S
COPENHAGEN, Denmark, July 23, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
Ascendis Pharma A/S Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH
September 26, 2017 08:00 ET | Ascendis Pharma A/S
COPENHAGEN, Denmark, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...